RPS6KA4 and neoplasm: MSKs have been shown to modulate the production of anti-inflammatory cytokines by controlling their transcription in macrophages and dendritic cells and promote cell death signalling through other pathways76, revealing that the BP and aCD47 combined treatment effectively inhibits tumour growth, probably involving MSK2 activation.